Meglumine antimoniate
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | P01CB01 (WHO) QP51AB01 (WHO) |
| Identifiers | |
| |
| CAS Number |
133-51-7 |
| PubChem (CID) | 64953 |
| ChemSpider |
58479 |
| UNII |
75G4TW236W |
| ChEMBL |
CHEMBL239129 |
| NIAID ChemDB | 008733 |
| ECHA InfoCard | 100.004.645 |
| Chemical and physical data | |
| Formula | Variable |
| Molar mass | Variable |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
See also
References
- ↑ Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical Infectious Diseases. 26 (1): 56–58. doi:10.1086/516267. PMID 9455509.
- ↑ Aventis press release, 15 April 2005. (German)
This article is issued from Wikipedia - version of the 9/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
